Compare Novo Nordisk A/S (NVO) vs Occidental Petroleum Corporation (OXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Occidental Petroleum Corporation — how do they compare? Novo Nordisk A/S trades at $38.16 (market cap $165.31B), while Occidental Petroleum Corporation trades at $60.14 (market cap $60.26B). The key difference: Novo Nordisk A/S is far larger — about 2.7× Occidental Petroleum Corporation's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Occidental Petroleum Corporation for 92 Days on average.
| NVO | OXY | |
|---|---|---|
Market Cap | $165.31B | $60.26B |
Volume | 11,432,838 | 11,718,920 |
Sector | Health | Energy |
52-Week High | $63.98 | $66.24 |
52-Week Low | $35.29 | $38.92 |
Typical Hold Time | 116 Days | 92 Days |
Enterprise Value | $179.56B | $79.02B |
Dividend Yield | 4.71% | 1.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
Occidental Petroleum (OXY) trades at $58.21, showing slight daily weakness but maintaining a bullish technical trend with strong fundamental metrics. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $2.40 significantly exceeding the $1.83 forecast. Valuation remains attractive with a P/E of 17.78 and EV/EBITDA of 5.56, while profitability metrics show robust margins and returns.
OXY presents compelling value with analyst consensus price target of $71.40 representing 23% upside potential. The company's debt reduction progress and strong cash flow generation support dividend sustainability. Key risks include oil price volatility and execution challenges in carbon management initiatives. Wall Street sentiment remains positive with 52% buy ratings among analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →
